• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Provention Bio Inc.

    2/14/22 5:29:22 PM ET
    $PRVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRVB alert in real time by email
    SC 13G 1 fp0072969_sc13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (AMENDMENT NO. )*

     

    PROVENTION BIO, INC.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    74374N102

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x]Rule 13d-1(b)
    [  ]Rule 13d-1(c)
    [  ]Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

    CUSIP No. 74374N102   13G   Page 1 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital (Master), L.P.

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,895,525

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    5,895,525

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,895,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     
      

     

    CUSIP No. 74374N102   13G   Page 2 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital GP, LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,895,525

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    5,895,525

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,895,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     


      

     

    CUSIP No. 74374N102   13G   Page 3 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital IM, L.P.

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,895,525

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    5,895,525

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,895,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     


      

     

    CUSIP No. 74374N102   13G   Page 4 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital IM GP, LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,895,525

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    5,895,525

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,895,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     


      

     

    CUSIP No. 74374N102   13G   Page 5 of 9 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    John Petry

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

     

    (a) [  ]

    (b) [  ]

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    5,895,525

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    5,895,525

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,895,525

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.3%

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     


      

     

    CUSIP No. 74374N102   13G   Page 6 of 9 Pages

     

    Item 1. (a)

    Name of Issuer

    Provention Bio, Inc.

         
      (b)

    Address of Issuer’s Principal Executive Offices

    55 Broad Street, 2nd Floor

    Red Bank, New Jersey 07701

     

    Item 2. (a)

    Name of Person Filing

    1.       Sessa Capital (Master), L.P.

    2.       Sessa Capital GP, LLC

    3.       Sessa Capital IM, L.P.

    4.       Sessa Capital IM GP, LLC

    5.       John Petry

         
      (b)

    Address of the Principal Office or, if none, residence

    888 Seventh Avenue, 30th Floor, New York, NY, 10019

         
      (c)

    Citizenship

    Sessa Capital (Master), L.P. is a Cayman Islands exempted limited partnership. Sessa Capital GP, LLC and Sessa Capital IM GP, LLC are Delaware limited liability companies. Sessa Capital IM, L.P. is a Delaware limited partnership. Mr. Petry is a citizen of the United States.

         
      (d)

    Title of Class of Securities

    Common Stock, par value $0.0001 per share (“Shares”)

         
      (e)

    CUSIP Number

    74374N102

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [  ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [  ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [  ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [  ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [x] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [  ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [  ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [  ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [  ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [  ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

      

     

    CUSIP No. 74374N102   13G   Page 7 of 9 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned:

     

    Sessa Capital (Master), L.P. (the “Fund”) directly beneficially owns 5,895,525 Shares.

     

    Sessa Capital GP, LLC is the general partner of the Fund and, as a result, may be deemed to beneficially own Shares owned by the Fund.

     

    Sessa Capital IM, L.P. is the investment manager of the Fund and, as a result, may be deemed to beneficially own Shares owned by the Fund.

     

    Sessa Capital IM GP, LLC is the general partner of Sessa Capital IM, L.P. and, as a result, may be deemed to beneficially own shares beneficially owned by Sessa Capital IM, L.P.

     

    Mr. Petry is the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC and, as a result, may be deemed to beneficially own shares owned by the Fund.

     

    (b)

    Percent of class:

    9.3%, based on 63,374,738 shares of Common Stock outstanding as of November 1, 2021, according to the Issuer’s quarterly report on Form 10-Q for the period ended September 30, 2021, which was filed with the Securities and Exchange Commission on November 4, 2021.

     

    (c) Number of shares as to which the person has:
      (i)

    Sole power to vote or to direct the vote:

     

    Sessa Capital (Master), L.P. may be deemed to have the sole power to vote or direct the vote of 5,895,525 Shares.

    Sessa Capital GP, LLC, Sessa Capital IM, L.P., Sessa Capital IM GP, LLC, and Mr. Petry may be deemed to have the sole power to vote or direct the vote of 5,895,525 Shares.

     

      (ii)

    Shared power to vote or to direct the vote:

     

    Not applicable

     

      (iii)

    Sole power to dispose or to direct the disposition of:

     

    Sessa Capital (Master), L.P. may be deemed to have the sole power to dispose or to direct the disposition of 5,895,525 Shares.

         
        Sessa Capital GP, LLC, Sessa Capital IM, L.P., Sessa Capital IM GP, LLC, and Mr. Petry be deemed to have the sole power to dispose or direct the disposition of 5,895,525 Shares.
         
      (iv)

    Shared power to dispose or to direct the disposition of:

     

    Not applicable

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ] .

      

     

    CUSIP No. 74374N102   13G   Page 8 of 9 Pages

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

      

     

    CUSIP No. 74374N102   13G   Page 9 of 9 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      By: /s/ John Petry  
        John Petry  
        John Petry, individually, as manager of Sessa Capital GP, LLC, the general partner of Sessa Capital (Master), L.P., and as manager of Sessa Capital IM GP, LLC, the general partner of Sessa Capital IM, L.P.  
           
      Date: February 14, 2022  

      

     

    SCHEDULE 13G

     

    CUSIP No. 74374N102

     

    EXHIBIT INDEX TO SCHEDULE 13G

     

    EXHIBIT 1

     

    Joint Filing Agreement, dated as of February 14, 2022, by and between Sessa Capital (Master), L.P., Sessa Capital GP, LLC, Sessa Capital IM, L.P., Sessa Capital IM GP, LLC, and John Petry.

      

    Get the next $PRVB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRVB

    DatePrice TargetRatingAnalyst
    9/20/2022$10.00Buy
    Jefferies
    11/23/2021Neutral → Outperform
    SMBC Nikko
    8/6/2021$18.00 → $16.00Outperform
    Oppenheimer
    8/6/2021$27.00 → $25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PRVB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.

      Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc. Paris, France – April 26, 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Sanofi's proposed acquisition of Provention Bio, Inc. (("Provention Bio", NASDAQ:PRVB) has expired. On March 24, 2023, Sanofi commenced a cash tender offer (the "Offer") to purchase all outstanding shares of common stock of Provention Bio (the "Shares"), for $25.00 per Share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law. As a result of the expiration of

      4/26/23 2:00:00 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

      RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, Marc

      3/13/23 7:00:00 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio Announces the Grant of Inducement Awards

      RED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a new  non-executive employee to purchase an aggregate of 10,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employee entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) and were approved by the Company's compensation committee of the board of directors.

      3/3/23 4:05:00 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    Financials

    Live finance-specific insights

    See more
    • Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call

      RED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, Marc

      3/13/23 7:00:00 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

      RED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will report its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (intern

      2/23/23 8:30:00 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D

      TZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune diseaseIn a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by 25 months, or approximately 2 years, compared to placeboStage 3 T1D is associated with significant health risks, including diabetic ketoacidosis, which can be life threateningPatients who progress to Stage 3 T1D eventually require insulin injections for lifeInvestor Conference call at 8:00am ET tomorrowRED BANK, N.J., Nov. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced

      11/17/22 5:45:00 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Provention Bio Inc. (Amendment)

      SC 13G/A - Provention Bio, Inc. (0001695357) (Subject)

      4/28/23 4:17:04 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Provention Bio Inc. (Amendment)

      SC 13G/A - Provention Bio, Inc. (0001695357) (Subject)

      4/5/23 8:51:26 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Provention Bio Inc.

      SC 13G - Provention Bio, Inc. (0001695357) (Subject)

      2/21/23 4:50:29 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Provention Bio with a new price target

      Jefferies initiated coverage of Provention Bio with a rating of Buy and set a new price target of $10.00

      9/20/22 7:52:57 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio upgraded by SMBC Nikko

      SMBC Nikko upgraded Provention Bio from Neutral to Outperform

      11/23/21 9:19:15 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Provention Bio with a new price target

      Oppenheimer reiterated coverage of Provention Bio with a rating of Outperform and set a new price target of $16.00 from $18.00 previously

      8/6/21 9:25:03 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TZIELD issued to PROVENTION BIO INC

      Submission status for PROVENTION BIO INC's drug TZIELD (ORIG-1) with active ingredient TEPLIZUMAB-MZWV has changed to 'Approval' on 11/17/2022. Application Category: BLA, Application Number: 761183, Application Classification:

      11/21/22 12:03:06 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    Leadership Updates

    Live Leadership Updates

    See more
    • Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

      RED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors. Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, Inc., AbbVie, Abbott Laboratories, and G.D. Searle and Co. prior to the latter's merger with Pharmacia & Upjohn and subsequent acquisition by Pfizer. "

      1/5/23 4:01:00 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

      RED BANK, N.J., Nov. 17, 2021 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Jan Hillson, M.D., as Senior Vice President of Clinical Development. Dr. Hillson bolsters the Company's clinical development leadership group with significant experience in all phases of clinical development across various autoimmune disorders, including systemic lupus erythematosus, which is the lead target indication for PRV-3279, a DART® (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B.

      11/17/21 7:30:00 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development

      RED BANK, N.J., Nov. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the appointment of Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development. Dr. Sanjuan further strengthens the Company's internal expertise in the core areas of immunomodulatory therapy, translational medicine and autoimmune disease. "As we continue to grow as an organization pioneering early interception and prevention of debilitating and life-threatening autoimm

      11/5/21 4:30:00 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sessa Capital (Master), L.P.

      4 - Provention Bio, Inc. (0001695357) (Issuer)

      4/28/23 4:18:32 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wysenski Nancy

      4 - Provention Bio, Inc. (0001695357) (Issuer)

      4/27/23 6:09:10 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pisano Wayne

      4 - Provention Bio, Inc. (0001695357) (Issuer)

      4/27/23 6:07:10 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRVB
    SEC Filings

    See more
    • SEC Form 15-12G filed by Provention Bio Inc.

      15-12G - Provention Bio, Inc. (0001695357) (Filer)

      5/8/23 4:17:48 PM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Provention Bio Inc.

      EFFECT - Provention Bio, Inc. (0001695357) (Filer)

      5/1/23 12:15:07 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Provention Bio Inc.

      EFFECT - Provention Bio, Inc. (0001695357) (Filer)

      5/1/23 12:15:31 AM ET
      $PRVB
      Biotechnology: Pharmaceutical Preparations
      Health Care